

# Raoul Charles Coombes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4698997/raoul-charles-coombes-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21  
papers

1,586  
citations

13  
h-index

23  
g-index

23  
ext. papers

1,819  
ext. citations

7.1  
avg. IF

3.35  
L-index

#	Paper	IF	Citations
21	Zinc stable isotopes in urine as diagnostic for cancer of secretory organs. <i>Metallomics</i> , <b>2021</b> , 13,	4.5	5
20	Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. <i>Annals of Oncology</i> , <b>2021</b> , 32, 681-684	10.3	3
19	Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1057-1060	10.3	0
18	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4255-4263	12.9	133
17	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 169-178	4.4	1
16	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. <i>Oncogene</i> , <b>2017</b> , 36, 2286-2296	9.2	99
15	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. <i>Oncogene</i> , <b>2016</b> , 35, 990-1002	9.2	131
14	New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM. <i>Faraday Discussions</i> , <b>2016</b> , 187, 539-53	3.6	21
13	Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 146-53	7.5	3
12	MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. <i>Oncology Reports</i> , <b>2016</b> , 35, 1170-8	3.5	21
11	Prognostic and predictive value of ER $\alpha$ and ER $\beta$ in the Intergroup Exemestane Study (IES)-first results from PathIES. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1890-1897	10.3	8
10	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in adrenergic signaling and enhances apoptosis. <i>Cell Death and Disease</i> , <b>2015</b> , 6, e1754	9.8	83
9	The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. <i>Cell Death and Differentiation</i> , <b>2014</b> , 21, 462-74	12.7	64
8	SUMOylation inhibits FOXM1 activity and delays mitotic transition. <i>Oncogene</i> , <b>2014</b> , 33, 4316-29	9.2	66
7	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. <i>Oncogene</i> , <b>2014</b> , 33, 4144-55	9.2	88
6	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 148, 581-90	4.4	62
5	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). <i>Annals of Oncology</i> , <b>2013</b> , 24, 924-30	10.3	11

4	Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. <i>Annals of Oncology</i> , <b>2010</b> , 21, 498-505	10.3	31
3	Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. <i>Lancet, The</i> , <b>2007</b> , 369, 559-70	40	712
2	High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. <i>Annals of Oncology</i> , <b>2005</b> , 16, 726-34	10.3	41
1	Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 592-592	2.2	2